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AbstrAct
Background Endobiliary stenting is standard practice for 
palliation of obstructive jaundice due to biliary tract cancer 
(BTC). Photodynamic therapy (PDT) may also improve 
biliary drainage and previous small studies suggested 
survival benefit.
Aims To assess the difference in outcome between 
patients with BTC undergoing palliative stenting plus PDT 
versus stenting alone.
Methods 92 patients with confirmed locally advanced 
or metastatic BTC, ECOG performance status 0–3 and 
adequate biliary drainage were randomised (46 per 
group) to receive porfimer sodium PDT plus stenting or 
stenting alone. The primary end point was overall survival 
(OS). Toxicity and progression-free survival (PFS) were 
secondary end points. Treatment arms were well balanced 
for baseline factors and prior therapy.
Results No significant differences in grade 3–4 toxicities 
and no grade 3–4 adverse events due to PDT were 
observed. Thirteen (28%) PDT patients and 24 (52%) 
stent alone patients received subsequent palliative 
chemotherapy. After a median follow-up of 8.4 months, OS 
and PFS were worse in patients receiving PDT compared 
with stent alone group (OS median 6.2 vs 9.8 months (HR 
1.56, 95% CI 1.00 to 2.43, p=0.048) and PFS median 3.4 
vs 4.3 months (HR 1.43, 95% CI: 0.93 to 2.18, p=0.10), 
respectively).
Conclusion In patients with locally advanced or 
metastatic BTC, PDT was associated with worse outcome 
than stenting alone, explained only in part by the 
differences in chemotherapy treatments. We conclude 
that optimal stenting remains the treatment of choice for 
malignant biliary obstruction and the use of PDT for this 
indication cannot be recommended outside of clinical 
trials.
Trial registration number ISRCTN 87712758; EudraCT 
2005-001173-96; UKCRN ID: 1461.
InTRoduCTIon
Cholangiocarcinoma and carcinoma of the 
gall bladder, collectively known as biliary tract 
cancer (BTC), are rare but highly aggressive 
malignancies associated with an unfavour-
able 5-year survival rate. Characterised by 
a relatively silent clinical course, they are 
often diagnosed at a late stage where cura-
tive resection can only be offered to <20% of 
patients.1 2 
In advanced and metastatic disease, the 
mainstay of treatment is limited to palliative 
chemotherapy using a combination treatment 
of gemcitabine and cisplatin with improved 
overall survival (OS).3 Palliative endoscopic 
or percutaneous biliary tree stenting allowing 
tumour-related biliary tract drainage, is often 
required in order to avoid life-threatening 
biliary obstruction and subsequent infec-
tion in non-resectable disease. Despite these, 
the prognosis remains poor with a median 
survival of <6 months in patients with complex 
hilar lesions.4 Nevertheless, novel palliative 
approaches are needed to improve quality of 
life and survival in this patient group.
Key questions
What is already known about this subject?
 ► In patients with obstructive jaundice due to unre-
sectable cholangiocarcinoma, small studies have 
suggested that photodynamic therapy (PDT) may 
improve biliary drainage and patient survival.
What does this study add?
 ► We conducted a large randomised controlled trial 
of porfimer sodium PDT in patients with confirmed 
locally advanced or metastatic biliary tract cancer.
 ► Patients undergoing PDT plus stenting had a worse 
outcome than those who underwent stenting alone.
How might this impact on clinical practice?
 ► We conclude that PDT for this indication cannot be 
recommended outside of clinical trials.
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Photodynamic therapy (PDT) consists of endoscopi-
cally accessed localised delivery of light (most conveniently 
from a low-power, red laser) after prior systemic admin-
istration of a photosensitising agent, thereby initiating a 
focal, non-thermal, cytotoxic effect, tissue necrosis and 
apoptosis.5 PDT has been used for palliation in patients 
with unresectable cholangiocarcinoma, with uncon-
trolled studies reporting an improvement in cholestasis, 
quality of life and survival of patients compared with 
historical controls.6 7 These results have been supported 
by small randomised controlled trials which report a 
survival benefit for PDT with stenting over stenting 
alone for unresectable cholangiocarcinoma. Ortner et al 
randomised 39 patients to stenting with or without PDT 
and demonstrated a survival advantage of 493 vs 98 days 
in favour of PDT.8 The patients in this study were those 
in whom jaundice could not be relieved by stenting, so 
it remains unclear whether PDT may also improve the 
survival of the majority of patients whose cholestasis can 
be relieved by biliary stenting. Zoepf et al randomised 
32 patients to stenting with or without PDT and demon-
strated a survival advantage of 21 vs 7 months in favour of 
PDT.9 These studies were small and in keeping with the 
standard of care at the time, few patients received pallia-
tive chemotherapy. Adverse events (AEs) related to PDT 
were minor and there was no early mortality. Cheon et 
al reported a retrospective analysis of 232 patients with 
cholangiocarcinoma, where the outcome in patients 
receiving PDT and endoscopic biliary drainage versus 
drainage alone was compared. Improved survival was 
observed in the PDT group with a median survival of 9.8 
months compared with 7.3 months in the stent alone 
group. Moreover, longer stent patency time was observed 
following PDT.10 Reports of other non-randomised trials 
exist in the literature. A meta-analysis which included 531 
subjects in five different trials (out of which 230 received 
PDT), reported improved survival after PDT compared 
with stenting alone.11 Lastly, in a three-centre, single-arm 
phase II trial of 36 patients with locally advanced BTC, we 
showed that PDT was associated with a low toxicity profile 
and a median survival of 12 months.12
Given these encouraging reports, a UK multicentre, 
randomised, phase III study was designed to assess the 
efficacy and safety of porfimer sodium PDT with biliary 
stenting versus biliary stenting alone in advanced or meta-
static BTC.
MATeRIAls And MeTHods
design
This was a multicentre, open-label randomised controlled 
phase III trial, designed and developed by the PHOTOS-
TENT-02 Trial Management Group under the auspices of 
the UK National Cancer Research Institute Upper Gastro-
intestinal Cancer Clinical Studies Group. The study was 
sponsored by the University College London and coordi-
nated by the Cancer Research UK and University College 
London Cancer Trials Centre. Regulatory approvals were 
obtained, and all patients gave written informed consent. 
The trial was run in accordance with the Declaration of 
Helsinki. An Independent Data Monitoring Committee 
regularly reviewed the data on safety and efficacy.
Patients
Patients were eligible if they had a histopathological 
or cytological diagnosis of non-resectable, recurrent 
or metastatic biliary tract carcinoma (intrahepatic or 
extrahepatic cholangiocarcinoma or gallbladder carci-
noma); had an ECOG performance status of 0, 1, 2 or 
3; were aged ≥18 years and had an estimated life expec-
tancy of >3 months. Patients were also required to have 
adequate biliary drainage before randomisation, with no 
evidence of active uncontrolled infection. Patients with 
highly suspicious findings for malignancy were permitted 
following central review and study entry was based on 
a case-by-case decision. Patients who had undergone 
non-curative surgery, had received prior radiotherapy 
and chemotherapy were eligible.
Patients were excluded if they had received treat-
ment with curative intent for current disease (ie, a 
prior resection, radical radiotherapy or chemotherapy) 
within the last 12 weeks; or palliative chemotherapy or 
radiotherapy within the previous 4 weeks. If they had 
any of these prior treatments, there had to have been 
clear evidence of disease progression prior to inclusion. 
Additional exclusion criteria included a history of prior 
malignancy that could interfere with response evalua-
tion, porphyria, pregnancy or breast feeding or lack of 
informed consent. Once the eligibility and exclusion 
criteria were checked at the registration telephone to 
the trial centre, patients were randomised to either 
PDT+stenting or stenting alone. Treatment allocation 
was given during the call and subsequently confirmed via 
fax and sent together with the case report forms. Rando-
misation used a minimisation algorithm, stratified for 
primary tumour site, disease extent (locally advanced 
vs metastatic), performance status, type of prior therapy 
and recruiting centre.
study entry
The initial patient evaluation included a history and 
physical examination, laboratory studies (complete 
blood count, biochemistry panel including liver 
biochemistry and tumour markers) and chest X-ray. 
In women of childbearing age, a negative serum preg-
nancy test was required. If not already done within the 
previous 4 weeks, tumour staging was performed by 
CT or MRI/cholangiopancreatography (MRI/MRCP) 
and diagnosis confirmed by endoscopic brush cytology 
or biopsy. If cytology or histology were negative at the 
first endoscopy, a repeat intervention (endoscopic retro-
grade cholangiopancreatography (ERCP), CT-guided or 
ultrasound-guided percutaneous needle biopsy or endo-
scopic ultrasound-guided fine-needle aspiration) was 
performed.
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Treatment
For entry into the study, all patients in both arms required 
adequate endoscopic or percutaneous biliary drainage 
and insertion of endoprosthesis into the right and left 
intrahepatic biliary tree up to 4 weeks before randomi-
sation. The placement of endoprosthesis was defined as 
technically successful when the stent bridged the main 
stricture to the right and/or left hepatic ducts ensuring 
sufficient passage of contrast medium through the stent 
into the duodenum (endoscopic plastic endoprosthesis, 
7–10 French (F) diameter, Cotton-Huibregtse type, Cook 
Ireland, Limerick). Oral ciprofloxacin was given before 
the ERCP and continued for at least 24 hours according 
to local hospital guidelines. Prior placement of uncov-
ered metal stents was not an exclusion criterion.
Once adequate biliary drainage had been achieved, 
patients randomised to stenting alone did not undergo 
repeat stenting unless clinically indicated. Those 
randomised to PDT and stenting received intravenous 
porfimer sodium (Photofrin; Axcan Pharma, Mont Saint-
Hilaire, Canada) at a dose of 2 mg/kg bodyweight. At 
ERCP 48 hours later, the previously placed endopros-
theses were removed, and endoluminal photoactivation 
performed either through a clear 10 F Huibregtse-Cotton 
endoscopic catheter introduced proximally above the 
strictures, or directly by inserting the laser quartz fibre 
(Medlight SA, Ecublens, Switzerland; 400 μm core diam-
eter, 20–50 mm cylindrical diffuser tip with an X-ray 
marker on both ends of the diffuser) directly across the 
stricture.
Photoactivation was performed at 630–635 nm using a 
light from a diode laser (Diomed, Cambridge, UK), with 
a linear diffuser exit dose of 186 J/cm, at linear irradi-
ance of 300 mW/cm. During the procedure, all patients 
received oxygen via a nasal catheter and conscious intra-
venous sedation with midazolam and fentanyl. A new set 
of endoprosthesis was inserted after the completion of 
treatment.
Patients remained on the ward in subdued lighting 
after administration of the photosensitiser, followed by 
re-adaptation to indirect sunlight for increasing periods 
during the morning and late afternoon of each day. 
Bright indoor light was permitted after the initial 2–3 days 
period. Patients were also given written and oral advice to 
avoid direct sunlight for 1–2 months. Patients randomised 
to stent alone were optimally stented, if necessary then 
proceeded to surveillance.
Assessment during and after treatment
In the PDT+stenting group, clinical and laboratory assess-
ments, including full blood count, urea and electrolytes, 
liver function tests, ECOG performance status, weight and 
clinical examination, were repeated at 7 and 28 days after 
light activation. Thereafter, patients in both trial groups 
were followed up at 3 monthly intervals. Formal tumour 
response evaluation by CT or MRI/MRCP was performed 
at 28 days and again at 6 and 12 months following admin-
istration of porfimer sodium.
Tumour response, by RECIST 1.0,13 was assessed radio-
logically (CT or MRI) at 3 and 6 months (post hoc anal-
ysis). Tumour control was defined as either complete 
response, partial response or stable disease; progressive 
disease was defined as either objective tumour progres-
sion or the confirmed emergence of local non-primary, 
metastatic or nodal disease. After study treatment had 
finished, patients were reviewed in clinic every 3 months 
until disease progression. Follow-up visits consisted 
of clinical assessment and either a CT or MRI scan to 
assess tumour status; once progressive disease was docu-
mented, patients were followed up for survival only.
Endoprostheses exchange was performed at 
6 monthly intervals or earlier if clinically indicated. In 
some patients with evidence of tumour progression at 
follow-up CT/MRI or ERCP, a second PDT was allowed 
at least 6 months after initial treatment. During the 
study period, patients could receive chemotherapeutic 
agents after day 28 at the discretion of their treating 
oncologist.
Assessment of adverse events and quality of life
Treatment-related toxicity was assessed at discharge and 
at each subsequent follow-up visit. All AEs were graded 
according to the National Cancer Institute Common 
Toxicity Criteria (V.3.0). The frequency of grade 3 and 
4 AEs has been reported by summarising the maximum 
grade experienced by each patient. Because patients were 
permitted to have abnormal liver biochemistry as long as 
adequate biliary drainage was achieved before randomi-
sation, grade 3/4 liver biochemical abnormalities at day 7 
and 28 were not regarded as AEs if they had been present 
before treatment.
statistical considerations
The primary outcome was OS and the secondary 
outcomes were progression-free survival (PFS) and AEs. 
The trial was designed to detect an increase in median 
survival of 4 months (or more), from 8 months in 
patients not receiving PDT to 12 months in those who 
did receive PDT (which was the lowest median survival 
in previous studies.7–9 To detect this difference in survival 
the trial required 240 patients to complete the study. 
This was based on 80% power, 5% statistical significance 
(two-sided) and assumed that the trial would recruit for 
up to 3 years with at least 12 months follow-up. Patients 
were randomised by telephoning the Cancer Research 
UK and University College London Cancer Trials Centre, 
which coordinated the trial.
All analyses were done on an intention-to-treat basis. 
The treatment difference of AEs was assessed by the test 
of proportions. OS was calculated from date of randomi-
sation until date of death. PFS was measured from rando-
misation until date of progression or death. Patients not 
having an event reported were censored at the date of 
their last follow-up. OS and PFS were analysed using 
Kaplan-Meier curves and Cox proportional hazards model 
was used to estimate the HR, comparing PDT versus stent 
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alone. All analyses were performed using Stata V.12.1 
(StataCorp, College Station, Texas, USA).
ResulTs
Patient characteristics
Figure 1 summarises the progression of patients through 
the trial; over a 28-month period, 92 patients were 
recruited (46 per group) from eight centres. There were 
55 males and 37 females, with a median age of 67.4 (range 
25.4–85.4) years. The two groups were well balanced for 
age, gender, disease stage and site, performance status 
and history of prior chemotherapy (table 1).
Recruitment was stopped on 18 December 2009 on 
advice of the Independent Data Monitoring Committee, 
after 92 patients had been recruited, and there had been 
a persistent difference in OS between the trial groups, in 
which those receiving PDT had worse survival. Follow-up 
data were collected on all patients entered into the trial 
until June 2011, when the database was closed for analysis. 
The five top recruiting sites then underwent independent 
quality assurance audit and monitoring to confirm adher-
ence to the protocol and Good Clinical Practice, and to 
verify the data. The Cancer Trials Centre also underwent 
an independent quality assurance audit.
Treatment compliance
All patients allocated to receive PDT did so, and the 
median time from randomisation to PDT treatment 
was 9 (range 5–12) days (table 2). PDT was technically 
successful in all patients, with light delivery performed 
after a median drug light interval of 48 (IQR range: 
44–48) hours. During follow-up, 41% and 54% of patients 
required repeat stenting in the PDT and stenting only 
arms, respectively, at a median of 2–3 months after 
randomisation. Four patients did not have a stent as per 
protocol—two per arm (figure 1).
survival and disease progression
At the time of the final analysis, median follow-up was 7.7 
months and 82 patients had died (76 from disease progres-
sion). There was one treatment-related death in the PDT 
arm secondary to a gallbladder empyema. OS was inferior 
in the PDT arm compared with stenting alone (median 
survival: 6.2 vs 9.8 months (HR 1.56, 95% CI 1.00 to 2.43, 
p=0.048); figure 2A). After adjusting for the randomisa-
tion stratification factors, the HR was 1.83, 95% CI 1.13 
to 2.96, p=0.014. The survival rate in the PDT arm at 12 
months was half that of the stent alone arm (20.3% vs 
40.3% survival).
Figure 1 Consolidated Standards of Reporting Trials 2010 flow diagram of patients in the PHOTOSTENT-02. PDT, 
photodynamic therapy.
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Forty-two (91%) and 46 (100%) of patients progressed 
or died in the stenting alone and PDT+stenting arms, 
respectively. There was weaker evidence of decreased 
PFS among the PDT patients (HR 1.43, 95% CI 0.93 to 
2.18, p=0.10; median PFS 3.4 vs 4.3 months; figure 2B); 
adjusting for stratification factors, HR 1.61 (95% CI 1.02 
to 2.54), p=0.042.
effect of chemotherapy on survival
Due to the unexpected adverse effect of PDT on survival, 
we investigated the possible reasons for this. Patients were 
permitted to have other therapies at least 28 days after 
randomisation (to allow for resolution of any AEs). A 
higher proportion of patients in the stent alone group 
received subsequent chemotherapy (24 patients (52%) vs 
13 patients (28%); p=0.02) and those who received it did 
so more rapidly following randomisation (median time 
to start of chemotherapy: 1.4 vs 4.4 months; p=0.005). We 
observed that receiving chemotherapy after randomisa-
tion was associated with a significantly improved survival. 
After adjusting for trial arm and baseline stratification 
factors, patients receiving chemotherapy were 85% less 
likely to die (HR 0.15 (95% CI 0.07 to 0.29), p<0.001. 
Median survival in patients who went on to receive 
chemotherapy was 13.0 vs 4.1 months for those who did 
not. Table 2 details that 50% of such patients received 
cisplatin and gemcitabine, the international standard for 
advanced disease. Another 25% received gemcitabine 
and 25% received another regimen. The impact of a 
differing chemotherapy regimen on survival is unlikely to 
have affected the outcome, in particular mortality within 
3 months of randomisation.
When comparing the OS between the two trial groups, 
adjusting for whether patients had chemotherapy or not 
after randomisation reduced the HR from 1.56 to 1.39 
(95% CI 0.89 to 2.17, p=0.15), that is, an approximate 
30% reduction. However, this factor did not fully explain 
the survival difference associated with PDT.
Adverse events
PDT was generally well tolerated; apart from liver toxic-
ities, there was only one grade 4 toxicity (sepsis) in the 
first month and one death secondary to empyema in 
the PDT arm. There was a single episode of ERCP-in-
duced pancreatitis but no episodes of major bleeding 
or photosensitivity reactions in the PDT group. No 
suspected unexpected serious adverse reactions were 
reported.
There were 39 patients (85%) with any grade 3–4 AE 
in the PDT arm compared with 30 (65%) in the 
stenting only group (p=0.030), which was partly due 
to a difference in bilirubin (37% (PDT+stent) vs 20% 
(stent alone); p=0.06; table 3). There were 36 patients 
with grade 3–4 liver function (bilirubin, alkaline phos-
phatase, alanine transaminase and gamma-glutamyl-
transferase) abnormality in the PDT arm compared 
with 28 in the stent only arm, the median survival of 
whom are 5.0 and 9.9 months, respectively (log-rank 
p=0.017) suggesting a detrimental effect of PDT on 
liver function that is associated with early death. There 
were more early deaths (within the first 3 months) in 
the PDT arm compared with stent only among those 
patients with any liver toxicity during treatment (PDT: 
39% (14/36); stent: 18% (5/28); p=0.068).
dIsCussIon
Local tumour progression and sepsis secondary to 
biliary outflow obstruction has a significant impact on 
the survival of patients with BTC. Insertion of plastic 
or metal endoprostheses can alleviate biliary obstruc-
tion, but stent occlusion with recurrent cholangitis is 
a frequent problem. It follows that improved drainage 
with PDT may improve survival and this, supported by 
encouraging results from small randomised trials, was 
the hypothesis for the current randomised study. Unex-
pectedly, there was a significant survival detriment asso-
ciated with PDT. This could be ascribed in part to less 
and later chemotherapy in the PDT arm, and potential 
late toxicity >1 month after PDT, as suggested by more 
early deaths associated with abnormal liver function.
Our findings were unexpected given the benefits of PDT 
reported elsewhere8 9 14 including a 12-month median 
survival in our own prior phase II PHOTOSTENT-01 
trial.12 The study hypothesis was based on the promising 
Table 1 Baseline characteristics of trial patients in the 
PHOTOSTENT-02 trial
PDT+stenting
n=46
N (%)
Stenting alone
n=46
N (%)
Sex 
  Male 29 (63) 26 (57)
  Female 17 (37) 20 (43)
Disease status
  Locally advanced 32 (70) 34 (74)
  Metastatic 14 (30) 12 (26)
Primary tumour site
  Gallbladder 3 (7) 5 (11)
  Bile duct 43 (93) 41 (89)
Prior therapy
  None 36 (78) 37 (80)
  Chemotherapy 7 (15) 7 (15)
  Other 3 (7) 2 (4)
ECOG performance status
  0 15 (33) 14 (30)
  1 21 (46) 20 (43)
  2 9 (20) 10 (22)
  3 1 (2) 2 (4)
Age (years), median 
(IQR) 67.7 (62.8–72.8) 67.3 (60.4–74.2)
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data from Ortner et al8 and Zoepf et al.9 These studies 
were small (total patient numbers: 39 and 32 patients; 
with 20 and 16 patients receiving PDT in each study, 
respectively) and were therefore not sufficiently strong to 
define practice. Moreover, some of the studies included 
patients who remained jaundiced despite stenting and 
very few patients received systemic treatment—all factors 
associated with inferior survival. Two recent meta-analyses 
of the available data have suggested a benefit of PDT on 
survival on quality of life in BTC, but concluded that there 
was significant heterogeneity and the quality of evidence 
was low.11 15 Although the current study was closed on the 
advice of the Independent Data Monitoring Committee 
after 92 patients had been enrolled, it remains the largest 
prospective study evaluating the role of PDT in this 
setting.
The ABC-02 study which was conducted contempo-
raneously to PHOTOSTENT-02 randomised patients 
between gemcitabine and cisplatin with gemcitabine 
(CisGem).16 This study established CisGem as the 
international standard for advanced BTC (the median 
OS was improved from 8.1 to 11.7 months, p<0.001), 
but this was not standard practice at the time of the 
smaller German and UK PHOTOSTENT-01 studies. 
In PHOTOSTENT-02, patients randomised to PDT 
were more likely to be placed on surveillance following 
PDT, whereas those randomised to stenting alone were 
more likely to receive systemic chemotherapy and to 
receive chemotherapy sooner. Adjusting for whether 
patients had subsequent chemotherapy suggests that 
the reduced use of and delayed time to systemic treat-
ment explained about 30% of the survival difference. 
Several other factors may also have played a role, in 
that patients randomised to PDT usually underwent 
an additional ERCP (with a greater risk of cholangitis) 
compared with the stenting alone group. To control 
for the effect of chemotherapy would require a study 
design that mandated standard chemotherapy but it 
Table 2 Treatment details of patients in the PHOTOSTENT-02 trial
PDT+stenting Stenting alone
P values
n=46
N (%)
n=46
N (%)
Time from randomisation to PDT (days)* 9 (5–12) NA
Patient underwent repeat biliary stenting
  No 27 (59) 21 (46) 0.21
  Yes 19 (41) 25 (54)
Number of separate restenting procedures
  1 9 (47) 11 (44) 0.55
  2 6 (32) 6 (24)
  >3 4 (22) 8 (32)
Time from randomisation to first restenting 
procedure (days)* 96 (74–139) 69 (46–134) 0.29
Additional treatments received
  Received chemotherapy 13 (28) 24 (52) 0.019
  Of which:
   Gemcitabine 3 8
   Gemcitabine+cisplatin 6 12
   Other chemotherapy regimen 4 4
  Time from randomisation until starting 
chemotherapy (days)* 135 (65–297) 43 (29–106) 0.005
  Other additional treatment 5 (11) 14 (30) 0.02
  Of which:
   Radiotherapy 2 3
   Other † 3 11
*Median (IQR). The Mann-Whitney U test was used to compare median time to event for only those patients who underwent repeat biliary 
stenting or received chemotherapy.
†Stent alone (11 patients, 14 records): ERCP (2); percutaneous transhepatic drainage (1); cancer bowel operation (1); percutaneous drainage 
of ruptured liver abscess (1); ascites drainage (1); palliative care (1); palliative gastrojejeunostomy (1); HDAC inhibitor (1); catheter inserted (1); 
nutritional support (1); antibiotics for cholangitis (1); bile acid sequestrant (1); antibiotics for chest infection (1). PDT (3 patients, 3 records): 
peritoneum transhepatic stent (1); palliative care (1); gentamycin and oral ciprofloxacin for sepsis (1).
ERCP, endoscopic retrograde cholangiopancreatography; HDAC, histone deacetylase; PDT, photodynamic therapy. 
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is uncertain whether this would have been feasible or 
reversed the significant adverse outcome described in 
this study. In a randomised phase II trial of PDT±che-
motherapy in patients with unresectable hilar cholan-
giocarcinoma, PDT plus the oral fluoropyrimidine, 
S-1 was well tolerated and associated with a significant 
improvement in OS compared with PDT alone (17 vs 8 
months, p=0.005).17
In conclusion, in this multicentre study, patients with 
BTC who received PDT in addition to optimal stenting 
had a poorer OS than those with stenting alone, which 
was only partly explained by fewer patients in the 
PDT arm receiving palliative chemotherapy. Based 
on these results, we conclude that optimal stenting 
remains the treatment of choice for malignant biliary 
obstruction, and that the use of porfimer sodium PDT 
Figure 2 Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival by treatment arm. (A) Median survival 
in the photodynamic therapy (PDT) and stent alone arms are 6.2 months (95% CI 3.5 to 9.2 months) and 9.8 months (95% CI 
6.5 to 12.8 months), HR 1.56 (95% CI 1.00 to 2.43), p=0.048. (B) Median progression-free survival in the PDT and stent alone 
arms are 3.4 months (95% CI 2.1 to 5.0 months) and 4.3 months (95% CI 3.1 to 5.7 months), HR 1.43 (95% CI 0.93 to 2.18), 
p=0.10.
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for this indication outside of clinical trials cannot be 
recommended.
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Table 3 Grade 3–4 adverse events during treatment in the PHOTOSTENT-02 trial
Adverse event
PDT+stenting
n=46
N (%)
Stenting alone
n=46
N (%) P values
Gamma-glutamyltransferase 28 (61) 22 (48) 0.21
Alkaline phosphatase 22 (48) 17 (37) 0.29
Bilirubin 17 (37) 9 (20) 0.064
Alanine transaminase 4 (9) 6 (13) 0.50
Anaemia 3 (7) 2 (4) 0.65
Albumin 3 (7) 2 (4) 0.65
Biliary sepsis 2 (4) 1 (2) 0.56
Pancreatitis 1 (2) 0 (0) 0.32
Photosensitivity 0 (0) 0 (0) –
Fever 0 (0) 0 (0) – 
Other toxicity 9 (20) 2 (4) 0.024
  Fatigue 2 (4) 0 (0)
  Ascites/abdominal bloating 2 (4) 0 (0)
  Prothrombin time 2 (4) 0 (0)
  Nausea 2 (4) 0 (0)
  Sepsis/septicaemia 1 (1) 1 (1)
  Cholangitis 1 (1) 0 (0)
  Vomiting 0 (0) 1 (1)
  Abdominal pain 1 (1) 0 (0)
  Urinary retention 0 (0) 1 (1)
  Constipation 1 (1) 0 (0)
  Insomnia 1 (1) 0 (0)
  Somnolence 1 (1) 0 (0)
Any toxicity 39 (85) 30 (65)
Absolute risk difference (95% CI) 19.6% (1.9 to 37.2%) 0.030
PDT, photodynamic therapy. 
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